FindTrial
Sign In

A study to compare the new reporting system that is the Paris system with previously used system in diagnosis of urinary bladder cancers by looking at cells in the urine

Comparative assessment of the Paris system for reporting urine cytology with the conventional system of reporting in the diagnosis of urinary bladder carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/08/020918
Enrollment
30
Registered
2019-08-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C679- Malignant neoplasm of bladder, unspecified

Interventions

Intervention1: Not applicable: Not applicable

Sponsors

Dr Vindhyaprabha Narayan Hegde
Lead Sponsor
Dr Nidhi Verma
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: All clinically suspected cases of urinary bladder carcinoma

Exclusion criteria

Exclusion criteria: All patients who have received chemotherapy and/or radiotherapy.

Design outcomes

Primary

MeasureTime frame
Proportion of high grade and low grade urinary bladder carcinoma detected by urine cytologyTimepoint: 1 year—

Secondary

MeasureTime frame
Comparison of the Paris system for reporting urine cytology with the conventional systemTimepoint: 1 year—

Countries

India

Contacts

Public ContactDr Nidhi Verma

Maulana Azad medical college

drnidhikamal@gmail.com8527271104

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026